Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels : the D:A:D study. / Kamara, David A; Smith, Colette; Ryom, Lene; Reiss, Peter; Rickenbach, Martin; Phillips, Andrew; Mocroft, Amanda; De Wit, Stephan; Law, Matthew; Monforte, Antonella d'Arminio; Dabis, Francois; Pradier, Christian; Lundgren, Jens D; Sabin, Caroline.

In: Antiviral Therapy, Vol. 21, No. 6, 2016, p. 495-506.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Kamara, DA, Smith, C, Ryom, L, Reiss, P, Rickenbach, M, Phillips, A, Mocroft, A, De Wit, S, Law, M, Monforte, ADA, Dabis, F, Pradier, C, Lundgren, JD & Sabin, C 2016, 'Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study', Antiviral Therapy, vol. 21, no. 6, pp. 495-506. https://doi.org/10.3851/IMP3051

APA

Kamara, D. A., Smith, C., Ryom, L., Reiss, P., Rickenbach, M., Phillips, A., Mocroft, A., De Wit, S., Law, M., Monforte, A. DA., Dabis, F., Pradier, C., Lundgren, J. D., & Sabin, C. (2016). Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study. Antiviral Therapy, 21(6), 495-506. https://doi.org/10.3851/IMP3051

Vancouver

Kamara DA, Smith C, Ryom L, Reiss P, Rickenbach M, Phillips A et al. Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study. Antiviral Therapy. 2016;21(6):495-506. https://doi.org/10.3851/IMP3051

Author

Kamara, David A ; Smith, Colette ; Ryom, Lene ; Reiss, Peter ; Rickenbach, Martin ; Phillips, Andrew ; Mocroft, Amanda ; De Wit, Stephan ; Law, Matthew ; Monforte, Antonella d'Arminio ; Dabis, Francois ; Pradier, Christian ; Lundgren, Jens D ; Sabin, Caroline. / Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels : the D:A:D study. In: Antiviral Therapy. 2016 ; Vol. 21, No. 6. pp. 495-506.

Bibtex

@article{3ea5a3512d804b0da132be3f036db1b9,
title = "Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study",
abstract = "BACKGROUND: Antiretroviral (ART) drugs have been associated with higher triglycerides (TG), higher total cholesterol (TC) and lower high-density lipoprotein cholesterol (HDL-C) levels. Associations between lipid levels with HIV viraemia and immunosuppression in the presence of ART remain unclear.METHODS: Participants from the D:A:D study with at least one TG/TC/HDL-C measurement were included. Linear mixed effect models were used to determine the association of ART, viral load (VL), nadir and current CD4(+) T-cell count and previous AIDS diagnosis with lipids.RESULTS: Of 49,717 participants, 90%, 92% and 80% contributed at least one TG/TC/HDL-C measurement (median follow-up 6.8, 6.8 and 5.0 years, respectively). Predicted mean (95% CI) baseline levels for TG, TC and HDL-C (mmol/l), were 2.10 (2.05, 2.14), 4.94 (4.91, 4.98) and 1.08 (1.07, 1.10), respectively. Lopinavir was associated with the worst TG profile, (27.2% higher levels compared to atazanavir; 95% CI 25.2%, 29.2%), and darunavir had a similar profile as atazanavir. The nucleoside pair lamivudine/tenofovir was associated with the most favourable TG profile (-2.8%; -3.5%, -2.0%) compared with emtricitabine/tenofovir, whereas lamivudine/abacavir (+10.2%; +9.3%, +11.2%) and lamivudine/stavudine (+8.0%; +6.9%, +9.0%), were associated with the worst. Raltegravir was associated with lower TG (-5.2%; -6.4%, -3.9%), and nevirapine had a more favourable HDL-C profile (+11.3%; +10.8%, +11.7%) than efavirenz (+5.3%; 5.0%, 5.7%), compared to atazanavir. Higher VLs were associated with lower TG/TC/HDL-C, whereas higher CD4(+) T-cell counts were associated with higher TG/TC/HDL-C.CONCLUSIONS: TG, TC and HDL-C levels, which generally improved over time, are dependent on ART, viraemia and, to a lesser extent, immunosuppression.",
author = "Kamara, {David A} and Colette Smith and Lene Ryom and Peter Reiss and Martin Rickenbach and Andrew Phillips and Amanda Mocroft and {De Wit}, Stephan and Matthew Law and Monforte, {Antonella d'Arminio} and Francois Dabis and Christian Pradier and Lundgren, {Jens D} and Caroline Sabin",
year = "2016",
doi = "10.3851/IMP3051",
language = "English",
volume = "21",
pages = "495--506",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press",
number = "6",

}

RIS

TY - JOUR

T1 - Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels

T2 - the D:A:D study

AU - Kamara, David A

AU - Smith, Colette

AU - Ryom, Lene

AU - Reiss, Peter

AU - Rickenbach, Martin

AU - Phillips, Andrew

AU - Mocroft, Amanda

AU - De Wit, Stephan

AU - Law, Matthew

AU - Monforte, Antonella d'Arminio

AU - Dabis, Francois

AU - Pradier, Christian

AU - Lundgren, Jens D

AU - Sabin, Caroline

PY - 2016

Y1 - 2016

N2 - BACKGROUND: Antiretroviral (ART) drugs have been associated with higher triglycerides (TG), higher total cholesterol (TC) and lower high-density lipoprotein cholesterol (HDL-C) levels. Associations between lipid levels with HIV viraemia and immunosuppression in the presence of ART remain unclear.METHODS: Participants from the D:A:D study with at least one TG/TC/HDL-C measurement were included. Linear mixed effect models were used to determine the association of ART, viral load (VL), nadir and current CD4(+) T-cell count and previous AIDS diagnosis with lipids.RESULTS: Of 49,717 participants, 90%, 92% and 80% contributed at least one TG/TC/HDL-C measurement (median follow-up 6.8, 6.8 and 5.0 years, respectively). Predicted mean (95% CI) baseline levels for TG, TC and HDL-C (mmol/l), were 2.10 (2.05, 2.14), 4.94 (4.91, 4.98) and 1.08 (1.07, 1.10), respectively. Lopinavir was associated with the worst TG profile, (27.2% higher levels compared to atazanavir; 95% CI 25.2%, 29.2%), and darunavir had a similar profile as atazanavir. The nucleoside pair lamivudine/tenofovir was associated with the most favourable TG profile (-2.8%; -3.5%, -2.0%) compared with emtricitabine/tenofovir, whereas lamivudine/abacavir (+10.2%; +9.3%, +11.2%) and lamivudine/stavudine (+8.0%; +6.9%, +9.0%), were associated with the worst. Raltegravir was associated with lower TG (-5.2%; -6.4%, -3.9%), and nevirapine had a more favourable HDL-C profile (+11.3%; +10.8%, +11.7%) than efavirenz (+5.3%; 5.0%, 5.7%), compared to atazanavir. Higher VLs were associated with lower TG/TC/HDL-C, whereas higher CD4(+) T-cell counts were associated with higher TG/TC/HDL-C.CONCLUSIONS: TG, TC and HDL-C levels, which generally improved over time, are dependent on ART, viraemia and, to a lesser extent, immunosuppression.

AB - BACKGROUND: Antiretroviral (ART) drugs have been associated with higher triglycerides (TG), higher total cholesterol (TC) and lower high-density lipoprotein cholesterol (HDL-C) levels. Associations between lipid levels with HIV viraemia and immunosuppression in the presence of ART remain unclear.METHODS: Participants from the D:A:D study with at least one TG/TC/HDL-C measurement were included. Linear mixed effect models were used to determine the association of ART, viral load (VL), nadir and current CD4(+) T-cell count and previous AIDS diagnosis with lipids.RESULTS: Of 49,717 participants, 90%, 92% and 80% contributed at least one TG/TC/HDL-C measurement (median follow-up 6.8, 6.8 and 5.0 years, respectively). Predicted mean (95% CI) baseline levels for TG, TC and HDL-C (mmol/l), were 2.10 (2.05, 2.14), 4.94 (4.91, 4.98) and 1.08 (1.07, 1.10), respectively. Lopinavir was associated with the worst TG profile, (27.2% higher levels compared to atazanavir; 95% CI 25.2%, 29.2%), and darunavir had a similar profile as atazanavir. The nucleoside pair lamivudine/tenofovir was associated with the most favourable TG profile (-2.8%; -3.5%, -2.0%) compared with emtricitabine/tenofovir, whereas lamivudine/abacavir (+10.2%; +9.3%, +11.2%) and lamivudine/stavudine (+8.0%; +6.9%, +9.0%), were associated with the worst. Raltegravir was associated with lower TG (-5.2%; -6.4%, -3.9%), and nevirapine had a more favourable HDL-C profile (+11.3%; +10.8%, +11.7%) than efavirenz (+5.3%; 5.0%, 5.7%), compared to atazanavir. Higher VLs were associated with lower TG/TC/HDL-C, whereas higher CD4(+) T-cell counts were associated with higher TG/TC/HDL-C.CONCLUSIONS: TG, TC and HDL-C levels, which generally improved over time, are dependent on ART, viraemia and, to a lesser extent, immunosuppression.

U2 - 10.3851/IMP3051

DO - 10.3851/IMP3051

M3 - Journal article

C2 - 27114439

VL - 21

SP - 495

EP - 506

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 6

ER -

ID: 169568244